Dopavision: Dopavision Completes Enrollment for MyopiaX-1 Trial
Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287).
Read full article »
Dopavision is a Germany-based biotechnology company that researches and develops ophthalmic digital therapeutics for the treatment of myopia.
Read more